Mark A. Velleca
CIK 1706847 · PRESIDENT & CEO · last filed 2026-01-23
Mark A. Velleca is a PRESIDENT & CEO who has filed 49 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for BDTX, was dated Jan 23, 2026. Across all open-market trades the lifetime net is −$8.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $194.9K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GTHX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
4501 RESEARCH COMMONS, SUITE 100
RESEARCH TRIANGLE PARK, NC 27709
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BDTX | PRESIDENT & CEO | 121,522 | $1.60 | $194.9K | $0 | 13 | 2026-01-23 |
| G1 Therapeutics, Inc. (GTHX) Delisted | Director | 173,286 | $7.15 | $1.24M | -$8.88M | 32 | 2023-08-10 |
Recent Filings
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-23 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2025-01-31 | BDTX | Grant (A) | +75,000 | $0 | EDGAR |
| 2024-04-09 | — | Notice (144) | −28,393 | -$136.4K | EDGAR |
| 2024-02-15 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2024-01-09 | — | Notice (144) | −60,000 | -$192.3K | EDGAR |
| 2023-12-12 | — | Notice (144) | −60,000 | -$203.9K | EDGAR |
| 2023-09-18 | BDTX | Grant (A) | +5,208 | $18.7K | EDGAR |
| 2023-08-10 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | — | -$96.8K | EDGAR |
| 2023-08-08 | — | Notice (144) | −60,000 | -$120.0K | EDGAR |
| 2023-06-16 | BDTX | Grant (A) | +8,929 | $18.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.